Small Molecule CMO/CDMO Market Expected to Hit $72.9 Billion by 2029, Growing at 7.6% CAGR

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Will Be the Forecast Market Size of the Global Small Molecule CMO/CDMO Market by 2029?
 The small molecule CMO/CDMO market size has grown strongly in recent years. It will grow from $50.58 billion in 2024 to $54.42 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to favorable government support, cost-effective solutions, growing complexity in drug development, industry consolidation, focus on core competencies.
 
 The small molecule CMO/CDMO market size is expected to see strong growth in the next few years. It will grow to $72.9 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to rise in drug pipelines, globalization of pharmaceutical operations, demand for flexible manufacturing, regulatory compliance expertise, biopharmaceutical convergence. Major trends in the forecast period include sustainable and green manufacturing practices, increased collaboration and partnerships, personalized medicine and niche therapies, rise in virtual and virtual-to-reality companies, integration of digital technologies, rapid response manufacturing.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13733&type=smp
 
 What Are the Leading Growth Factors in the Small Molecule CMO/CDMO Market?
 The rising demand for pharmaceuticals is expected to propel the growth of the small-molecule CMO/CDMO market going forward. The pharmaceutical industry is a sector that involves the discovery, development, and production of drugs and medicines by both governmental and private entities. Small-molecule CMO/CDMO is used in the pharmaceutical industry to outsource various services, including the development, manufacturing, and packaging of small-molecule drugs, allowing pharmaceutical companies to reduce costs, save time, and streamline processes. For instance, in August 2024, according to the Government of Canada, a Canada-based government agency, domestic exports in the pharmaceutical sector rose to 9.59 billion USD (12.79 billion CAD) in 2022, up from 10.71 billion CAD in 2021. Imports also increased, reaching 30.21 billion CAD compared to 26.63 billion CAD in 2021. Therefore, the rising demand for pharmaceuticals is driving the growth of the small-molecule CMO/CDMO market.
 
 Which Segment Offers the Highest Growth Opportunities in the Small Molecule CMO/CDMO Market?
 The small molecule cmo/cdmo market covered in this report is segmented — 
 
 1) By Product: Small Molecule Drug Product, Small Molecule API
 2) By Stage Type: Clinical, Commercial, Preclinical
 3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Cardiovascular Disease, Respiratory Disorders, Metabolic Disorders, Other Therapeutics
 4) By Application: Cardiovascular, Oncology, Diabetes, Immunological Disorders
 
 Subsegments:
 1) By Small Molecule Drug Product: Solid Dosage Forms (Tablets, Capsules), Liquid Dosage Forms (Injectables, Solutions), Topical Dosage Forms 
 2) By Small Molecule API (Active Pharmaceutical Ingredient): Generic APIs, Branded APIs, Custom Synthesis APIs
 
 What Are the Major Trends Impacting the Small Molecule CMO/CDMO Market?
 Major companies operating in the small-molecule CMO/CDMO market are focusing on innovative technologies, such as the state-of-the-art small-molecule platform in Shanghai, to elevate CDMO services. The state-of-the-art small-molecule platform represents the forefront of technological innovations to develop and produce small-molecule drugs and to create safer, more effective, and more efficiently produced pharmaceutical compounds. For instance, in June 2023, Porton Pharma Solutions Ltd., a China-based pharmaceutical company, launched a state-of-the-art small-molecule platform in Shanghai, elevating CDMO services. A state-of-the-art small molecule platform embodies a holistic approach, combining cutting-edge technologies and methodologies to advance the entire lifecycle of small molecule pharmaceuticals and one-stop-shop solutions, an end-to-end platform, flexibility and availability, and digital transformation.
 
 Who Are the Leading Companies in the Small Molecule CMO/CDMO Industry by Revenue?
 Major companies operating in the small molecule CMO/CDMO market report are Patheon NV (Thermo Fisher Scientific), GlaxoSmithKline, Johnson Matthey PLC, Lonza Group Ltd., WuXi AppTec, Catalent Inc., Aurobindo Pharma, Fareva, Aesica Pharmaceuticals Limited, Siegfried holdings AG, Recipharm AB, Jubilant Life Sciences Limited, Almac Group, Piramal Pharma Solutions, Oxford Chemicals Inc., Syngene International Limited, Novasep, Pfizer CentreOne, GVK Biosciences, ChemPartner, Avid Bioservices Inc., Dishman Carbogen Amcis Ltd., ProChem Inc., Metrics Contract Services
 
 Get the full small molecule cmo/cdmo market report here:
 https://www.thebusinessresearchcompany.com/report/small-molecule-cmo-or-cdmo-global-market-report
 
 What Are the Regional Opportunities for Investment in the Small Molecule CMO/CDMO Market?
 North America was the largest region in the small molecule CMO/CDMO market in 2024. The regions covered in the small molecule CMO/CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company